Table 5. Multivariate analysis of predictors for AF recurrence in rs6795970 genotypes in an additive model.
| Multivariate analysis | ||
|---|---|---|
| OR (95% CI) | P | |
| rs6795970 genotype (AA vs. GA vs. GG) | 0.36 (0.22~0.60) | 7.04 × 10−5 |
| Sex (female vs. male) | 1.07 (0.64~1.78) | 0.798 |
| Age (≥60 vs. <60 years old) | 1.05 (0.65~1.70) | 0.829 |
| AF subtype (paroxysmal vs. non-paroxysmal) | 0.79 (0.38~1.67) | 0.543 |
| History of AF (≥36 vs. <36 months) | 3.57 (2.26~5.63) | 4.33 × 10−8 |
| LAD (≥40 vs. <40 mm) | 1.85 (1.08~3.19) | 0.026 |
| LVEF | 0.98 (0.94~1.01) | 0.191 |
| Hypertension (with vs. without) | 0.75 (0.47~1.21) | 0.244 |
| Coronary heart disease (with vs. without) | 0.83 (0.31~2.21) | 0.703 |
| Rheumatic heart disease (with vs. without) | 2.03 (0.46~8.94) | 0.348 |
| Cerebral embolism (with vs. without) | 0.57 (0.19~1.74) | 0.323 |
| Diabetes (with vs. without) | 1.85 (1.00~3.42) | 0.051 |
| Smoking (with vs. without) | 0.57 (0.19~1.74) | 0.171 |
| Alcohol (with vs. without) | 1.69 (0.63~4.53) | 0.296 |
| Amiodarone use (with vs. without) | 1.00 (0.59~1.70) | 0.997 |
| BB use (with vs. without) | 1.01 (0.63~1.64) | 0.956 |
| CCB use (with vs. without) | 0.91 (0.44~1.88) | 0.800 |
| ACEI/ARB use (with vs. without) | 0.93 (0.57~1.50) | 0.764 |
| Linear ablations (with vs. without) | 0.78 (0.46~1.33) | 0.361 |
| CFAEs ablations (with vs. without) | 1.38 (0.69~2.78) | 0.365 |
| Cardioversion during ablation (with vs. without) | 1.88 (0.89~3.95) | 0.097 |
Note: AF: atrial fibrillation; LAD: left atrial diameter; LVEF: left ventricular ejection fraction; BB: beta-receptor blocker; CCB: calcium channel blocker; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker. CFAEs: complex fractionated atrial electrograms.